Thermo Fisher Scientific | TMO - Equity Capital And Reserves


Thermo Fisher Scientific reported $51.93B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Abbott USD 52.06B 69M Mar/2026
Agilent USD 7.12B 214M Mar/2026
Becton, Dickinson and Co. USD 24.13B 1.15B Mar/2026
Bio Techne USD 2.09B 74.32M Mar/2026
Bio-Rad Laboratories USD 6.85B 602.3M Mar/2026
Boston Scientific USD 25.86B 1.63B Mar/2026
Bruker USD 2.46B 35.9M Dec/2025
Charles River Laboratories USD 2.9B 265.94M Mar/2026
Danaher USD 52.95B 415M Mar/2026
Dentsply International USD 1.32B 21M Mar/2026
Edwards Lifesciences USD 10.33B 10.1M Mar/2026
General Electric Aerospace USD 18.06B 841M Mar/2026
Henry Schein USD 3.27B 21M Mar/2026
Illumina USD 2.68B 47M Mar/2026
Intuitive Surgical USD 17.47B 349.5M Mar/2026
IQVIA Holdings USD 6.22B 282M Mar/2026
Laboratory Of America USD 8.73B 108.8M Mar/2026
Medtronic USD 48.99B 128M Dec/2025
Mettler Toledo International USD -41.88M 18.25M Mar/2026
Myriad Genetics USD 337.4M 30.6M Mar/2026
Olympus JPY 812.04B 38.69B Mar/2026
OraSure Technologies USD 313.32M 27.5M Mar/2026
Quest Diagnostics USD 7.37B 196M Mar/2026
Repligen USD 2.11B 666K Mar/2026
Revvity USD 7.25B 125.54M Dec/2025
Stryker USD 22.42B 635M Dec/2025
Thermo Fisher Scientific USD 51.93B 1.6B Mar/2026
Veracyte USD 1.34B 34.83M Mar/2026
Waters USD 2.56B 230.55M Dec/2025
Zimmer Biomet Holdings USD 12.68B 16.1M Mar/2026